Loading...

BCRX BIOCRYST PHARMACEUTICALS INC Contract Awards 8-K Filing

BCRY

BCRX

BIOCRYST PHARMACEUTICALS INC

(BCRX)

2024 8-K

Show Summary

Show Summary

New Product Launches

Financial Statements

Management Changes

CFO Resignation

Financial Results

Investor Conference

Q3 Financial Results

Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval

Financial Results Announcement

Financial Results Announcement

By-Laws Amendment

Financial Results

Departure of Directors

Commercialization Agreement...

Regulation FD Disclosure

License Agreement for Avora...

Financial Results Announcement

Clinical Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval of ...

Financial Results and Busin...

External Links:

BioCryst Pharmaceuticals announced a contract with the U.S. Department of Health and Human Services worth up to $69 million to supply 95,625 doses of RAPIVAB over five years, with an initial order of $13.9 million for 19,125 doses.

AI Assistant

BIOCRYST PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.